ovarian cancer

Olaparib Phase 3 Development Discontinued by AstraZeneca

(January 1, 2012) In a surprise announcement, AstraZeneca put out a press release in late December announcing the cancellation Phase 3 development for olaparib. The official reason given for abandoning development was as follows: “The decision to discontinue olaparib’s development in serous ovarian cancer was made following a review of an interim analysis of a …

Olaparib Phase 3 Development Discontinued by AstraZenecaRead More »